JMJacob Eifer Møller

Jacob Eifer Møller

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jacob Eifer Møller has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Resource utilization associated with extracorporeal membrane oxygenation vs. microaxial flow pump for infarct-related cardiogenic shock

    by Margriet Bogerd, Luc Ten Hoorn, Sanne Ten Berg, Elma J Peters, Annemarie E Engström, Arjan Malekzadeh, Holger Thiele, Jacob E Møller, Christian Hassager, Alexander P J Vlaar, et al.

    Aims: Microaxial flow pump and venoarterial extracorporeal membrane oxygenation (VA-ECMO) are increasingly used in infarct-related cardiogenic shock. This study provides a comparative overview of real-world resource utilization associated with these devices (PROSPERO: CRD42024505174). Methods and results: EMBASE, MEDLINE, and Cochrane Library were sought from inception to 13 November 2024 for studies reporting at least one primary outcome, including intensive care unit (ICU) length of stay (LOS), hospital LOS, in-hospital costs, and discharge destination. In-hospital mortality was included as secondary outcome. This study was guided by the PRISMA-2020 guideline. Study selection and data extraction were independently performed by two researchers. Risk-of-bias assessments were done using the Newcastle-Ottawa-Scale. Data were pooled using random-effect models. In total, 12 retrospective cohorts were identified encompassing 92 262 microaxial flow pump- and 16 474 VA-ECMO patients data. The meta-analysis of hospital LOS and in-hospital costs revealed favourable results for the microaxial flow pump, with mean differences (MD) of −5.3 days (95% CI: −6.6, −4.1) and −$113 983 (95% CI: −$143 153, −$84 812), respectively. Microaxial flow pump survivors were also 45% more likely to be discharged home (95% CI: 1.28–1.64). Intensive care unit-length of stay was reported by one study, reporting a 10 days MD in favour of the microaxial flow pump. The averaged in-hospital mortality rates were 44% and 57% for the microaxial flow pump and VA-ECMO, respectively. An inherent limitation of observational studies is confounding by indication. Conclusion: Microaxial flow pump was associated with lower resource utilization compared with VA-ECMO. Resource utilization should be incorporated in prospective RCTs and taken into account when considering these devices.


  • Extracorporeal cardiopulmonary resuscitation: a national study on the association between favourable neurological status and biomarkers of hypoperfusion, inflammation, and organ injury

    by Emilie Gregers, Sivagowry Rasalingam Mørk, Louise Linde, Jo Bønding Andreasen, Morten Smerup, Jesper Kjærgaard, Peter Hasse Møller-Sørensen, Lene Holmvang, Steffen Christensen, Christian Juhl Terkelsen, et al.

    In refractory out-of-hospital cardiac arrest (OHCA) with prolonged whole-body ischemia, global tissue injury proceeds even after establishment of circulation with extracorporeal cardiopulmonary resuscitation (ECPR). We aimed to investigate the role of biomarkers reflecting hypoperfusion, inflammation, and organ injury in prognostication of patients with refractory OHCA managed with ECPR. This nationwide retrospective study included 226 adults with refractory OHCA managed with ECPR in Denmark (2011-2020). Biomarkers the first days after ECPR-initiation were assessed. Odds ratio of favorable neurological status (Cerebral Performance Category 1-2) at hospital discharge were estimated by logistic regression analyses. Cut-off values were calculated using the Youden’s index. Fifty-six patients (25%) survived to hospital discharge, 51 (91%) with a favorable neurological status. Factors independently associated with favorable neurological status were low flow time 9/L, admission lactate <13.2 mmol/L, alkaline phosphatase (ALP) < 56 (day1) or <55 U/L (day2), and day 1 creatine kinase MB (CK-MB) < 500 ng/mL. Selected biomarkers (leukocytes, C-reactive protein, and lactate) were significantly better predictors of favorable neurological status than classic OHCA-variables (sex, age, low-flow time, witnessed arrest, shockable rhythm) alone (p = 0.001) after hospital admission. Biomarkers of hypoperfusion (lactate), inflammation (leukocytes), and organ injury (ALP and CK-MB) were independently associated with neurological status at hospital discharge. Biomarkers of hypoperfusion and inflammation (at hospital admission) and organ injury (days 1 and 2 after ECPR) may aid in the clinical decision of when to prolong or terminate ECPR in cases of refractory OHCA.